Vivos Inc. Expands IsoPet® Therapy with New Clinic Partnership
Vivos Inc. Expands IsoPet® Therapy with New Clinic Partnership
Vivos Inc. (OTCQB: RDGL) has recently taken a significant step in enhancing its offerings for animal cancer treatment by certifying a new clinic dedicated to IsoPet® Precision Radionuclide Therapy™. The announcement signals Vivos Inc.'s commitment to expanding the accessibility and effectiveness of this innovative cancer treatment for small animals.
Introducing NorthStar Vets to IsoPet Therapy
The newly certified clinic, NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, now provides comprehensive emergency and trauma care, along with specific specialty services geared towards small animals. Their recent approval to administer IsoPet therapy marks a crucial addition to their existing range of treatments.
Commitment to Expanding Access
Dr. Michael K. Korenko emphasized the importance of expanding the number of clinics certified for IsoPet therapy. He noted that certification not only offers a lower-cost alternative compared to other treatments requiring hefty capital investments but also fosters a collaborative environment among veterinarians and oncologists committed to its success. Vivos provides the necessary training and support as clinics navigate the complexities of obtaining or updating their radioactive material licenses.
Understanding the IsoPet Therapy Process
IsoPet therapy utilizes advanced Yttrium-90 based technology to deliver precise and targeted treatment for tumors. This innovative technique administers radiation directly to the tumor site, minimizing side effects typically associated with traditional external radiation therapies. By embedding a radioactive isotope within the tumor area, IsoPet can provide a higher dose of treatment without impacting surrounding healthy tissues.
Benefits of RadioGel® in Cancer Treatment
The RadioGel® product, utilized alongside IsoPet®, is designed to retain its therapeutic properties at room temperature and gel upon injection into the tumor. This method helps secure the radioactive particles in place, ensuring that the radiation remains localized, maximizing its efficacy while protecting adjacent organs from exposure.
Evidencing Effectiveness through Research
Research conducted at prestigious veterinary institutions has demonstrated the safety and effectiveness of IsoPet therapy. Studies examining the treatment of feline sarcoma and canine soft tissue sarcomas have confirmed its therapeutic benefits. Notably, the FDA recognized IsoPet as a medical device, facilitating its integration into veterinary practices.
The Path Forward for IsoPet® Therapy
As Vivos Inc. continues on its trajectory of innovation, the company aims to introduce more clinics to IsoPet therapy, thereby reaching a broader scope of animal patients in need of effective cancer treatments. The emphasis on utilizing already established facilities ensures that the transition towards adopting IsoPet therapy is seamless and beneficial for both pet owners and veterinary practices.
Frequently Asked Questions
What is IsoPet® Precision Radionuclide Therapy™?
IsoPet® is an advanced cancer treatment designed for small animals that utilizes targeted radiation to effectively destroy tumors while minimizing harm to surrounding tissues.
How does the certification process for clinics work?
The certification process involves Vivos Inc. assisting clinics in navigating regulatory requirements, including obtaining or amending radioactive material licenses, alongside providing comprehensive training.
Why is Yttrium-90 important in this therapy?
Yttrium-90 is crucial because it emits localized radiation directly where it is needed, allowing for effective tumor treatment without affecting nearby healthy organs.
What are the main advantages of IsoPet therapy compared to traditional treatments?
IsoPet therapy allows for a higher localized dose of radiation, can be administered in an outpatient setting, and generally results in fewer side effects compared to traditional external beam radiation therapies.
Is IsoPet therapy FDA approved?
Yes, the FDA recognizes IsoPet as a medical device, confirming its safety and intended use in treating specific types of cancers in animals.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Rosen Law Firm Supports DexCom, Inc. Investors Facing Losses
- Savara Inc. Grants Inducement Awards to New Employees
- FDA Advances Health Innovations with Recent Approvals
- Opportunities for Sunlight Financial Holdings, Inc. Investors
- Boston Scientific Unveils New Cardiac Mapping Technology
- Nasdaq Inc. Achieves Historic Stock Surge as Investors Cheer
- Whitestone REIT Reaches New Heights with Promising Growth
- Bumble Inc. Securities Fraud: Know Your Rights as an Investor
- Central Federal Corp Achieves New Stock Milestone with Growth Surge
- Ape On Revolutionizes Token Launches with Enhanced Security Measures
Recent Articles
- CleanCore Solutions Rings NYSE Opening Bell to Celebrate Growth
- How Affluent Americans Are Shaping Retail Spending Trends
- SeaStar Medical's Pivotal Trial Enrollment Shows Strong Progress
- Top Growth Stocks You Should Consider Investing In Now
- Norwegian Cruise Line Holdings Adjusts Earnings Announcement Timing
- Marjorie Taylor Greene's Strategic Investments in AI Stocks
- FibroBiologics and Charles River Unite for Cell Therapy Advancements
- HeartCore's Q3 2024 Results Show Strong Growth Trends
- Oragenics, Inc. Set to Share Innovations at Key Summit
- Fancamp Launches Comprehensive Survey for Gold Exploration
- SEALSQ and Allion Japan Team Up for Seamless IoT Security
- P10 Announces Third Quarter Earnings Release with Conference Call
- Arcutis Gains Health Canada Approval for Innovative Dermatitis Treatment
- Upcoming Meeting for Shareholders of Kaspi.kz to Discuss Key Decisions
- Essential Disclosure for Balanced Commercial Property Trust
- Bradley L. Radoff Critiques GSE Systems Board on Merger Deal
- Exploring Denmark's Thriving Loyalty Programs Market Trends
- Investors Alert: Top Tech Stocks Facing Major Risks Ahead
- Valour's Strategic ETP Move: A New Chapter in Nordic Crypto
- Diageo Celebrates HBCU Heritage with Homecoming Initiatives
- Zhangshu Trade Fair Showcases Global Traditional Medicine Trends
- Marcum's Survey Shows Manufacturing Sector's Robust Adaptation
- Buena Vida y Salud ACO Celebrated for Value-Based Care Innovation
- Joe Weiss Joins PLT Health Solutions as Brand Management Head
- Heliogen's New CTO Set to Propel Solar Innovations
- Mothercare's Resilience: Profits Amidst Sales Challenges
- Valvoline's CFO Transition: A New Chapter Ahead for VVV
- Vertex Pharmaceuticals Showcases Pivotal Pain Medication Data
- Fifth Third Bancorp Faces Decline in Profit Due to Higher Provisions
- Porsche's Stock Surge Driven by Customization Demand and Premium Models
- Understanding Bitcoin's Price Dynamics: Critical Levels to Watch
- US Economic Growth Indicates Positive Trends for Future Quarters
- Druckenmiller Reflects on Nvidia Investment Mistakes and AI Future
- Transformative Changes Shaping the Anatomic Pathology Market
- Playtika Sets Conference Call for Q3 2024 Financial Results
- PodcastOne Unveils 'Zero Stars' Podcast: A Fresh Take on Criticism
- Immunome to Showcase Novel ROR1-ADC at Major Oncology Symposium
- Helius Medical Technologies to Showcase Innovations at Key Conference
- Exciting New Home Community Launched by KB Home in Florida
- Alignment Healthcare Sets Stage for Q3 2024 Financial Call
- Vertex Pharmaceuticals Showcases Pivotal Phase 3 Data for Suzetrigine
- SpaceX and NASA Partner for Upcoming ISS Missions in 2025
- Madrigal Pharmaceuticals Plans Exciting Q3 Financial Results Event
- Ferring Pharmaceuticals Showcases Innovations in Fertility Care
- FOREWARN Partners with REALTORS® for Enhanced Safety Tools
- Bitcoin's Surge: Impact on Altcoins and Future Strategies
- Key Updates on Tryg Share Trading Activity Among Executives
- Cyber A.I. Group Partners to Drive Strategic Growth Initiatives
- Heliogen Welcomes Apurba Das as the New CTO to Drive Innovation
- Octopus Future Generations VCT Enhances Offering Strategy